[1]McLean MH, El-Omar EM. Genetics of gastric cancer[J]. Nat Rev Gastroenterol Hepatol, 2014, 11(11):664-674.
[2]Kalni?a Z, Meistere I, Kikuste I, et al. Emerging blood-based biomarkers for detection of gastric cancer[J]. World J Gastroenterol, 2015, 21(41):11636-11653.
[3]Chen XL, Chen XZ, Yang C, et al. Docetaxel, cisplatin and fluorouracil (DCF) regimen compared with non-taxane-containing palliative chemotherapy for gastric carcinoma: a systematic review and meta-analysis[J]. PLoS One, 2013, 8(4):e60320.
[4]Kashyap D, Mondal R, Tuli HS, et al. Molecular targets of gambogic acid in cancer: recent trends and advancements[J]. Tumour Biol, 2016, 37(10):12915-12925.
[5]Wang LH, Li Y, Yang SN, et al. Gambogic acid synergistically potentiates cisplatin-induced apoptosis in non-small-cell lung cancer through suppressing NF-κB and MAPK/HO-1 signalling[J]. Br J Cancer, 2014, 110(2):341-352.
[6]Zhang W, Zhou H, Yu Y, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression[J]. Onco Targets Ther, 2016, 9:3359-3368.
[7]Zhao W, Xia SQ, Zhuang JP, et al. Hypoxia-induced resistance to cisplatin-mediated apoptosis in osteosarcoma cells is reversed by gambogic acid independently of HIF-1α[J]. Mol Cell Biochem, 2016, 420(1-2):1-8.
[8]Chen PM, Cheng YW, Wu TC, et al. MnSOD overexpression confers cisplatin resistance in lung adenocarcinoma via the NF-κB/Snail/Bcl-2 pathway[J]. Free Radic Biol Med, 2015, 79:127-137.
[9]Kim CW, Lu JN, Go SI, et al. p53 restoration can overcome cisplatin resistance through inhibition of Akt as well as induction of Bax[J]. Int J Oncol, 2013, 43(5):1495-1502.
[10]Dong H, Liu G, Jiang B, et al. Overexpression of the Survivin gene in SGC7901 cell resistance to cisplatin[J]. Oncol Lett, 2014, 8(5):1953-1956.
[11]Cadoni E, Valletta E, Caddeo G, et al. Competitive reactions among glutathione, cisplatin and copper-phenanthroline complexes[J]. J Inorg Biochem, 2017, 173:126-133.
[12]Wortelboer HM, Balvers MG, Usta M, et al. Glutathione-dependent interaction of heavy metal compounds with multidrug resistance proteins MRP1 and MRP2[J]. Environ Toxicol Pharmacol, 2008, 26(1):102-108.
[13]Inoue K, Fry EA, Frazier DP. Transcription factors that interact with p53 and Mdm2[J]. Am J Transl Res, 2017, 9(3):1127-1138.
[14]Chen YJ, Chen SY, Lovel R, et al. Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2[J]. Oncol Lett, 2016, 12(3):2107-2114.
[15]Zhan M, Qu Q, Wang G, et al. Let-7c sensitizes acquired cisplatin-resistant A549 cells by targeting ABCC2 and Bcl-XL[J]. Pharmazie, 2013, 68(12):955-961.
[16]Zhang W, Zhou H 1, Yu Y, et al. Combination of gambogic acid with cisplatin enhances the antitumor effects on cisplatin-resistant lung cancer cells by downregulating MRP2 and LRP expression[J]. Onco Targets Ther, 2016, 9:3359-3368.
[17]Lin YT, Liu YC, Chao CC. Inhibition of JNK and prothymosin-alpha sensitizes hepatocellular carcinoma cells to cisplatin[J]. Biochem Pharmacol, 2016, 122:80-89.
[18]Seino M, Okada M, Sakaki H, et al. Time-staggered inhibition of JNK effectively sensitizes chemoresistant ovarian cancer cells to cisplatin and paclitaxel[J]. Oncol Rep, 2016, 35(1):593-601.
[19]Lo Iacono M, Monica V, Vavalà T, et al. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway[J]. Int J Cancer, 2015, 136(11):2598-2609.
[20]Liu Y, Chen X, Gu Y. FOXM1 overexpression is associated with cisplatin resistance in non-small cell lung cancer and mediates sensitivity to cisplatin in A549 cells via the JNK/mitochondrial pathway[J]. Neoplasma, 2015, 62(1):61-71.
|